Comments
Major Indian drug-makers are likely to acquire a host of Israel-based Teva Pharmaceuticals’ products as a fall out of a proposed acquisition of Allergan’s generic pharmaceutical business by Teva.
According to a notification from the US Federal Trade Commission (USFTC), the acquisition of 79 existing and future products from Teva by 11 firms, including Dr Reddy’s Laboratories Ltd, Cipla and Aurobindo Pharma will ‘eliminate anti-competitive effects of the proposed acquisition’.
Thus, the acquisition of Teva’s products in select markets is a pre-condition for approving Teva-Allergan deal. In July 2015, Teva proposed to acquire Allergan’s generic pharma business for approximately $40.5 billion. It is then required to submit a consent agreement to the USFTC in order to preserve competition. It is in this consent agreement section that Teva had disclosed that it divest rights and assets to the acquirers, including Mayne Pharma Group, Impax Laboratories, Inc, Dr Reddy’s Labs, Cipla and Aurobindo. In June 2016, Hyderabad-based Dr Reddy’s had entered into a definitive agreement with Teva and an arm of Allergan plc to acquire a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the US for $350 million in cash.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.